1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > ARCHIVE
ARCHIVE
- LDP Summarizes Its Proposals for Healthcare Reform
November 26, 2001
- Post-marketing Safety Is Int'l Issue: Dr Doi
November 26, 2001
- Marketing Approval Is Being Considered by Korosho : Seminar
November 26, 2001
- REGULATORY NEWS IN BRIEF
November 26, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 26, 2001
- DIAGNOSTIC NEWS IN BRIEF
November 26, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -2-
November 26, 2001
- WORLD NEWS IN BRIEF
November 26, 2001
- BULLETIN
November 26, 2001
- The 39th Annual Meeting of Japan Society of Clinical Oncology
November 26, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -1-
November 26, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
November 26, 2001
- Precautions of 4 Drugs Including Carboplatin Revised Due to ADR
November 19, 2001
- WORLD NEWS IN BRIEF
November 19, 2001
- REGULATORY NEWS IN BRIEF
November 19, 2001
- Sankyo Aims at US Sales of \360 Bil. in FY2010
November 19, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 19, 2001
- Shionogi to Increase Overseas Sales to 10% of Total Sales in 2005
November 19, 2001
- NEW PRODUCTS
November 19, 2001
- Otsuka, BMS File NDA for New Antipsychotic Aripiprazole with FDA
November 19, 2001
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…